Suggested remit: To appraise the clinical and cost effectiveness of aficamten within its marketing authorisation for treating symptomatic obstructive hypertrophic cardiomyopathy.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- Cost Comparison Standard
- ID number:
- 6575
Provisional Schedule
- Committee meeting:
- 01 June 2026
- Expected publication:
- 05 August 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
Stakeholders
- Companies sponsors
- Aficamten (Cytokinetics UK)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Arrhythmia Alliance
- Atrial Fibrillation Association
- Cardiac Risk in the Young
- Cardiomyopathy UK
- Cardiovascular Care Partnership
- Circulation Foundation
- Gene People
- Genetic Alliance UK
- Haemochromatosis UK
- HEART UK
- Pumping Marvellous
- Somerville Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Professional groups
- Association of Genetic Nurses and Counsellors
- British Association for Nursing in Cardiovascular Care
- British Atherosclerosis Society
- British Cardiovascular Intervention Society
- British Cardiovascular Society
- British Geriatrics Society
- British Heart Foundation
- British Nuclear Cardiology Society
- British Society of Echocardiography
- British Society for Gene and Cell Therapy
- British Society for Genetic Medicine
- British Society for haemostasis and thrombosis
- British Society for Heart Failure
- British Society of Cardiovascular Imaging
- Clinical Leaders of Thrombosis (CLOT)
- National Heart and Lung Institute
- Primary Care Cardiovascular Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for Cardiological Science and Technology
- Society for Vascular Nurses
- Society for Vascular Technology of Great Britain and Ireland
- UK Clinical Pharmacy Association
- Vascular Society of Great Britain and Ireland
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Bristol Myers Squibb (mavacamten)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Government
- NHS Wales Joint Commissioning Committee
- Relevant research groups
- Cardiac and Cardiology Research Dept, Barts
- Genomics England
- Heart Research UK
- MRC Clinical Trials Unit
- National Institute for Health Research
- National Centre for Cardiovascular Preventions and Outcomes
- British Society for Cardiovascular Research
- Wellcome Trust
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 February 2026 | Invitation to participate |
| 31 October 2025 - 02 December 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6575 |
| 31 October 2025 | In progress. Scoping commencing |
| 02 October 2025 | To appraise the clinical and cost effectiveness ofAficamten within its marketing authorisation for treating hypertrophic cardiomyopathy ID6575 |
| 15 April 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual